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Abstract 
Heterozygous point mutations or deletions of the NKX2-1 gene cause benign hereditary chorea 
(BHC) or a various combinations of primary hypothyroidism, respiratory distress and neurological 
disorders. Deletions proximal to, but not encompassing, NKX2-1 have been described in few 
subjects with brain-lung-thyroid syndrome. We report on a three-generation Italian family, with 6 
subjects presenting BHC and harboring a genomic deletion adjacent to NKX2-1 and including the 
gene MBIP, recently proposed to be relevant for the pathogenesis of brain-lung-thyroid syndrome. 
We observed a clear reduction of NKX2-1 transcript levels in fibroblasts from our patients 
compared to controls; this finding suggests that MBIP deletion affects NKX2-1 expression, 
mimicking haploinsufficiency caused by classical NKX2-1 related mutations. 
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Introduction 
Several NKX2-1 point mutations or deletions of chromosome 14 encompassing NKX2-1 have been 
associated with Benign Hereditary Chorea (BHC) [Breedveld et al. 2002; Thorwarth et al. 2014; 
Peall & Kurian 2015]. All patients were heterozygous for the mutation, therefore suggesting a 
dominant mode of inheritance. NKX2-1 encodes a transcription factor, which is expressed during 
early development of thyroid, lung and forebrain regions. Accordingly, in addition to BHC, patients 
with NKX2-1 mutations presented combinations of primary hypothyroidism, respiratory distress and 
neurological disorders. Few cases with BHC or brain-lung-thyroid syndrome have been reported to 
harbor deletions proximal to, but not disrupting, NKX2-1 [Barnett et al. 2012;.Thorwarth et al. 
2014; Kharbanda et al. 2017]. 
Here we describe a three-generation Italian family, with 6 subjects presenting with BHC and 
harboring a genomic deletion adjacent to NKX2-1 and including the gene MBIP, recently proposed 
to be relevant for the pathogenesis of brain-lung-thyroid syndrome [Kharbanda et al. 2017]. 
Patients’ Data  
The probands were two siblings (III-1 and III-2, pedigree in Figure 1) with a very similar clinical 
picture (Table 1) consisting of hypotonia and motor delay, a hyperkinetic movement disorder noted 
since infancy and recurrent pulmonary infections. They both presented dysmorphic features 
(macrocephaly, prominent and large forehead, big round eyes, bilateral hallux valgus), oculomotor 
apraxia and generalized chorea with superimposed irregular myoclonic jerks. Cognitive functions 
were within normal limits. A younger half-sister (III-3) was referred for motor delay and 
unbalanced gait with frequent falls at age 4. The father (II-3) was affected by an early-onset, non 
progressive chorea and pulmonary pathology (severe asthma); after age 30, he suffered episodes of 
hypotension and hypoglycaemia. His brother (II-5) presented mild chorea associated with minor 
cognitive and psychiatric involvement; at age 35 he was diagnosed with lung carcinoma. Their 
grandmother (I-1) had only a mild early-onset chorea and she did not experience any pulmonary 
disease.  
Thyroid function was measured in all cases during the follow-up and always resulted normal. The 
movement disorder spontaneously improved over time in all cases, causing little or no functional 
disability.  
Methods 
Informed consent for the genetic diagnosis was obtained from patients or parents according to the 
local regulations, DNA was extracted from venous peripheral blood lymphocytes according to 
standard procedures and was used as a template to amplify the 3 exons of the NKX2-1 gene. PCR 
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fragments were analyzed by automated nucleotide sequencing using the Big-Dye terminator Ready 
Reaction Kit version 2 on a 3100 Genetic Analyzer Automated Sequencer (Applied Biosystems).  
Haplotype analysis was performed by SNPs array (ILLUMINA HumanCytoSNP-12 BeadChip). 
For whole exome sequencing (WES),  genomic DNA was processed for library enrichment 
according to the SeqCap EZ Exome v3.0 kit (Roche). Sequencing was performed on an Illumina® 
Genome Analyzer HiSeq2500. The sequencing reads were aligned to the National Center for 
Biotechnology Information human reference genome (GRCh37/hg19) using the Burrows-Wheeler 
Aligner (BWA). Variant calling was performed using Genome Analysis Toolkit (GATK) and 
VariantStudio Data Analysis Software (Illumina®) was used for variants annotation and filtering. 
Coverage analysis was performed on WES data of individuals I-1 and III-2 using CANOES 
(http://www.columbia.edu/~ys2411/canoes). CANOES is a bioinformatics tool based on an 
algorithm for the detection of rare copy number variants from exome sequencing data; it uses a 
regression-based approach on selected reference samples in a given dataset to estimates variance of 
the read counts for an affected sample. 
For gene content analysis, real-time quantitative PCR (RT-qPCR) was performed using SYBR 
Green chemistry and primers specific to MBIP exon 1 and 8, with a single copy gene (RNaseP) 
taken as a nuclear gene reference. For the analysis of transcripts, total RNA was extracted from 
fibroblasts patient, according to the manufacturer’s instructions (RNeasy Mini Kit Qiagen). RT-
qPCR assay on cDNA (Go TaqR 2 step RTqPCR System) was performed using three different 
primers specific for amplification of NKX2-1 and and one house-keeping gene (ACTB).  
Results 
Because of the clinical presentation, we sequenced NKX2-1 in the proband III-1 but no mutation 
was found. In order to identify the genetic defect, we performed SNP-array analysis and WES. 
SNP-array analysis on available DNAs from the family revealed a genomic deletion on 
chr14:36206651-36321589 [GRCh38/hg38] (LOVD Variant ID: 0000352599) in 5 affected family 
members, absent in two unaffected cases (Figure 1). The identified deletion was near NKX2-1, but 
not encompassing this gene. Only one gene, MBIP (encoding MAP3K12 binding inhibitory protein 
1), was included in the deleted region (Figure 1). WES was performed on individuals I-1 and III-2. 
Filtering steps using chorea genes (NKX2-1, SGCE, SLC16A2, ADCY5) as a bait, did not identified 
any candidate variants shared by the two affected cases. Because of the negative results from WES 
and the published evidence that copy number changes in next proximity to NKX2-1 may cause a 
phenotype comparable to that of intragenic mutations [Kharbanda et al. 2017; Thorwarth et al. 
2014], we pointed our attention to the chr14q13 deletion. We demonstrated the heterozygous 
deletion of MBIP in all affected members of the family (Figure 1) by quantitative PCR. Moreover, a 
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deep analysis of WES coverage data further confirmed this finding, highlighting that only MBIP has 
a halved copy number whereas the surrounding genes, including NKX2-1, were not affected 
(Supplementary Figure S1). In order to evaluate any possible effect of the MBIP deletion on NKX2-
1 expression, we measured NKX2-1 transcript levels in patients II-3, III-1 and III-2. Despite the low 
expression of NKX2-1 in fibroblasts, we observed a clear reduction of NKX2-1 transcript levels in 
our patients compared to controls, although slightly lower than the decrease observed in fibroblasts 
from two patients harboring mutations in NKX2-1 (Supplementary Figure S2). 
Discussion  
The deletion we identified comprises a single gene, MBIP, not associated with any human disease. 
Notably, deletion of MBIP was present in all reported cases of 14q13 deletion adjacent to but not 
directly involving NKX2-1 [Barnett et al. 2012;.Thorwarth et al. 2014; Kharbanda et al. 2017]  
(Figure 1). 
All these data suggest two possible, non-exclusive, mechanisms: 1) MBIP impairment is directly 
related  to the pathogenesis of BHC and other brain-lung-thyroid syndromes; 2) MBIP deletion 
affects genomic elements important for NKX2-1 expression, resulting in NKX2-1 impairment, as for 
the classical BHC cases. 
Data in support of both hypotheses have been published. An identical pattern of temporal and 
spatial expression for MBIP and NKX2-1, including basal ganglia, forebrain, thyroid and lung, was 
reported [Thorwarth et al. 2014]; moreover, the chromosomal region encompassing the two genes is 
part of one of the largest synteny blocks in humans [Santagati et al. 2003]. These findings may 
indicate that both genes are important for the same biological process, i.e. the proper development 
and function of brain, lung and thyroid. Nevertheless, the known roles of MBIP protein seem not 
directly related or coincident to NKX2-1 and its expression regulation of thyroid-specific genes and 
genes involved in morphogenesis. Lastly, no point mutations in MBIP were found in 74 BHC 
patients, previously negative for NKX2-1 mutations [Thorwarth et al. 2014] or have ever been 
described, despite the wide and growing use of WES in several genetic diseases, including 
movement disorders [Singleton 2012], arguing against a direct role of MBIP dysfunction in BHC. 
Conversely, our data from patients’ fibroblasts provide an experimental support to the hypothesis 
that a secondary impairment of NKX2-1, due to a deletion of the adjacent genomic region 
comprehending MBIP, mimics NKX2-1 haploinsufficiency and can explain the overlapping 
phenotype between deletions outside of NKX2-1 and intragenic NKX2-1 mutations. 
Predicted enhancer elements for NKX2-1 have been reported in the deleted region of previous cases 
with BHC and without a direct involvement NKX2-1, suggesting that these elements could 
contribute to the observed phenotype and the impairment of NKX2-1 transcription we observed in 
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cells from our patients [Kharbanda et al. 2017]. Another  possible explanation is that these deletions 
hit topologically associating domains (TADs), blocks of chromatin which are fundamental, not only 
for genome organization but also for genomic function [Dixon et al. 2016]. It has been shown that 
TADs play important roles in modulating transcription [Gorkin et al. 2014] and their disruption may 
result in disease [Lupianez et al. 2016]. The genomic region including NKX2-1 and MBIP may be 
part of a TAD and deletion of portion of this domain could alter the expression of all or part of the 
contained genes. 
In conclusion, our data indicate that deletion of the MBIP gene  is associated with benign hereditary 
chorea, possibly lowering NKX2-1 expression and thus mimicking haploinsufficiency caused by 
NKX2-1 mutations. 
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Figure legend 
Figure 1: Pedigree of the investigated family and genetic analyses 
A. SNP-array analysis, performed on all available DNAs from the family (8 subjects: 6 affected and 
2 healthy cases), revealed a genomic heterozygous deletion on chr14q13 in 5 affected family 
members, absent in two unaffected cases. The poor quality of the DNA from individual I-1 led to its 
exclusion from the analysis. Real-time quantitative PCR showed the heterozygous deletion of MBIP 
on genomic DNAs in all affected members of the family. Labels indicate the presence (del) or 
absence (no_del) of the 14q13 deletion by SNP-array analysis (in dark blue) or the MBIP deletion 
by RT-qPCR (in red). 
B. Map of the Chr.14 genomic region surrounding MBIP and NKX2-1 genes, with the deletions 
identified in our family and in previously published cases. 
 
Table 1. Clinical features of the affected family members 
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Patient Neurological Respiratory Thyroid Psychiatric Other 
features 
III-1 Hypotonia, 
generalized 
chorea, myoclonic 
jerks 
Recurrent 
pulmonary 
infections 
/ Mild cognitive 
impairment 
Dysmorphisms 
III-2 Hypotonia, 
generalized 
chorea, myoclonic 
jerks, ataxia 
Recurrent 
pulmonary 
infections 
/ / Dysmorphisms, 
macrocrania 
III-3 Motor delay, 
unbalanced gait 
/ / / / 
II-3 Chorea Severe asthma / / Hypotension, 
hypoglycaemia 
II-5 Mild chorea Lung carcinoma / Minor cognitive 
and psychiatric 
involvement 
/ 
I-1 Mild chorea / / / / 
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Supplementary Material includes 2 figures and is available online. 
Supplementary Figure S1: Analysis of the coverage data from whole exome sequencing 
Supplementary Figure S2: NKX2-1 transcript analysis 
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